Judy M. Coulson

ORCID: 0000-0003-2191-2001
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Occupational and environmental lung diseases
  • Medical Imaging and Pathology Studies
  • Cancer Research and Treatments
  • Ubiquitin and proteasome pathways
  • Lung Cancer Research Studies
  • Neuroendocrine Tumor Research Advances
  • Enzyme Structure and Function
  • Advanced Proteomics Techniques and Applications
  • Neuroendocrine regulation and behavior
  • Cancer-related Molecular Pathways
  • Epigenetics and DNA Methylation
  • RNA Research and Splicing
  • Cancer Genomics and Diagnostics
  • Microtubule and mitosis dynamics
  • Ocular Oncology and Treatments
  • Neonatal Respiratory Health Research
  • Peptidase Inhibition and Analysis
  • HER2/EGFR in Cancer Research
  • Genetics and Neurodevelopmental Disorders
  • Protein Kinase Regulation and GTPase Signaling
  • Neuropeptides and Animal Physiology
  • Genomics and Chromatin Dynamics
  • RNA modifications and cancer
  • DNA and Nucleic Acid Chemistry
  • Biotin and Related Studies

University of Liverpool
2016-2025

University of Oxford
2023

John Wiley & Sons (United Kingdom)
2023

Hudson Institute
2023

John Wiley & Sons (United States)
2023

Nottingham City Hospital
1999-2004

University of Nottingham
1999-2004

Cancer Research UK
2003-2004

Ontario Institute for Cancer Research
2004

Princess Margaret Cancer Centre
2004

Immunotherapy using immune checkpoint inhibitors (ICIs) induces durable responses in many metastatic cancers. Metastatic uveal melanoma (mUM), typically occurring the liver, is one of most refractory tumours to ICIs and has dismal outcomes. Monosomy 3 (M3), polysomy 8q, BAP1 loss primary (pUM) are associated with poor prognoses. The presence tumour-infiltrating lymphocytes (TILs) within pUM surrounding mUM - some evidence clinical adoptive TIL transfer strongly suggests that UMs indeed...

10.1002/path.5384 article EN cc-by-nc-nd The Journal of Pathology 2020-01-21

Radioresistance is the major cause of cancer treatment failure. Additionally, splicing dysregulation plays critical roles in tumorigenesis. However, involvement alternative resistance cells to radiotherapy remains elusive. We sought investigate key role factor SRSF1 radioresistance lung cancer.Lung cell lines, xenograft mice models, and RNA-seq were employed study detailed mechanisms radioresistance. Clinical tumor tissues TCGA dataset utilized determine expression levels distinct...

10.1016/j.ebiom.2018.11.007 article EN cc-by-nc-nd EBioMedicine 2018-11-11

Abstract Uveal melanoma (UM) is a rare aggressive intraocular tumour with propensity for liver metastases, occurring in ∼50% of patients. The suppressor BAP1 considered to be key UM progression. Herein, we present the largest study date investigating cellular expression patterns protein 165 UMs, correlating these prognosis. Full clinical, histological, genetic, and follow‐up data were available all gene sequencing was performed on subset 26 cases. An independent cohort 14 UMs examined...

10.1002/cjp2.86 article EN cc-by-nc The Journal of Pathology Clinical Research 2017-10-16

The phosphatidylinositol-3-kinase (PI3K) pathway is commonly hyperactivated in cancer. One mechanism by which this occurs silencing of the phosphatase and tensin homolog (PTEN), a tumor suppressor major antagonist pathway, through genetic, epigenetic or posttranscriptional mechanisms. Here, we used an unbiased siRNA screen non-small-cell lung cancer cells to identify deubiquitylases (DUBs) that have impact on PI3K signaling regulating abundance PTEN. We found PTEN expression was induced...

10.1038/onc.2013.512 article EN cc-by Oncogene 2013-12-02

Physical inactivity and disuse are major contributors to age-related muscle loss.Denervation of skeletal has been previously used as a model with which investigate atrophy following disuse.Although gene regulatory networks that control after denervation have established, the transcriptome in response recovery associated epigenetic mechanisms may function modulate expression during or yet be investigated.We report silencing tibialis anterior rats tetrodotoxin (TTX)-administered common...

10.1096/fj.201700089rr article EN The FASEB Journal 2017-08-17

Ras proteins are important signalling hubs frequently dysregulated in cancer and a group of developmental disorders called Rasopathies. Three genes encode four that differentially contribute to these phenotypes. Using quantitative real-time PCR (qRT-PCR) we have measured the gene expression profiles each isoforms panel mouse tissues derived from full time course spanning embryogenesis through adulthood. In most stages observe relative contribution KRas4B > NRas ≥ KRas4A HRas total with...

10.1038/srep41297 article EN cc-by Scientific Reports 2017-01-24

// Joseph J. Sacco 1 , Jenna Kenyani Zohra Butt Rachel Carter Hui Yi Chew 1, 2 Liam P. Cheeseman 3 Sarah Darling Michael Denny Sylvie Urbé Clague Judy M. Coulson Cellular & Molecular Physiology, Institute of Translational Medicine, University Liverpool, UK Current address: Cancer Stem Cell Biology, Agency for Science Technology and Research, Genome Singapore, Singapore MRC Laboratory Cambridge, Correspondence to: Coulson, e-mail: j.m.coulson@liv.ac.uk Keywords: histone deacetylase...

10.18632/oncotarget.3765 article EN Oncotarget 2015-04-24

Lung cancer, particularly small cell lung cancer (SCLC), is characterized by production of numerous peptides and their resulting clinical syndromes. Such can act as autocrine growth factors for these tumors. In this study, we investigated the role endothelin (ET)-1 in cancer. Using reverse transcription/polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay, immunocytochemistry, screened a panel lines ET-1, its receptors, converting enzyme-1 (ECE-1), which generates active...

10.1165/ajrcmb.22.4.3795 article EN American Journal of Respiratory Cell and Molecular Biology 2000-04-01

Reversible ubiquitylation of proteins contributes to their integrity, abundance and activity. The RE1-silencing transcription factor (REST) plays key physiological roles is dysregulated in a spectrum disease. It rapidly turned over phosphorylated, polyubiquitylated degraded en masse during neuronal differentiation cell cycle progression. Through siRNA screening we identified the deubiquitylase USP15 as regulator cellular REST. Both antagonism REST polyubiquitylation rescue endogenous levels...

10.4161/cc.25035 article EN Cell Cycle 2013-06-15

Abstract Purpose: Specific markers of circulating tumor cells may be informative in managing lung cancer. Because the RE-1 silencing transcription factor (REST/NRSF) is a transcriptional repressor that inactivated neuroendocrine cancer, we identified REST-regulated transcripts (CHGA, CHGB, SCG3, VGF, and PCSK1) for evaluation as biomarkers peripheral blood. Experimental Design: Transcripts were screened across cancer normal cell lines. Candidates assessed by reverse transcription-PCR...

10.1158/1078-0432.ccr-08-1163 article EN Clinical Cancer Research 2008-12-31

Ubiquitin-specific protease 15 (USP15) is a widely expressed deubiquitylase that has been implicated in diverse cellular processes cancer. Here we identify topoisomerase II (TOP2A) as novel protein regulated by USP15. TOP2A accumulates during G2 and functions to decatenate intertwined sister chromatids at prophase, ensuring the replicated genome can be accurately divided into daughter cells anaphase. We show USP15 required for accumulation, depletion leads formation of anaphase chromosome...

10.1038/s41388-017-0092-0 article EN cc-by Oncogene 2018-02-08

Abstract The nuclear deubiquitylase BRCA1-associated protein 1 (BAP1) is frequently inactivated in malignant pleural mesothelioma (MPM) and germline BAP1 mutation predisposes to cancers including MPM. To explore the influence on cell physiology drug sensitivity, we sequentially edited a predisposition (w-) promoter trap (KO) into human mesothelial cells. BAP1w-/KO MeT5A cells express less phenocopy key aspects of loss Stable isotope labeling with amino acids culture–mass spectrometry...

10.1158/1541-7786.mcr-22-0635 article EN cc-by Molecular Cancer Research 2023-01-20
Coming Soon ...